Thymosin Alpha-1 Price Comparison — Compare 23 Vendors

View full research →
Immune-modulation researchSafety Rating 8/10

Price Comparison

Compare vendors · per 5mg

23 vendors competing

VendorPrice$ / mgUpdated
Ascension Peptides8.5/10$37.50$75.00−50% · code peptidepri$3.75Apr 16, 2026Buy →
Optimum Formula8.5/10$40.49$44.99−10% · code PEPTIDEPRICES$4.05May 14, 2026Buy →
Hydro Research9/10$52.00$65.00−20% · code PEPTIDEP20$5.20Jun 5, 2026Buy →
Glacier Aminos9.5/10$57.59$63.99−10% · code peptidep$5.76Jun 23, 2026Buy →
GLP-1 Research Lab8/10$60.00$6.00Jun 19, 2026Buy →
Amino Club10/10$31.99$39.99−20% · code PEPTIDEPRICES$6.40May 14, 2026Buy →

Research details

Thymosin Alpha-1 — research data

Research-literature reference data, NOT patient instructions. Not for human use. Consult a licensed clinician for any human application.

Research dose range900 mcg–1.6 mg SC twice weekly. Standard course: 6 months. Acute immune support: 1.6 mg/day for 2 weeks.
AdministrationSubcutaneous injection
Safety8/10 · Approved in 30+ countries
NCAA D1Not listed

Overview

About Thymosin Alpha-1

Mechanism of action

Endogenous peptide derived from thymosin fraction 5; modulates T-cell differentiation and maturation; upregulates MHC class I expression; stimulates dendritic cells; potentiates NK cell activity.

Safety profile

Very well-tolerated. Injection site reactions; rare flu-like symptoms. Decades of safety data. · 11,000+ patients in 30+ trials; well-tolerated; approved as Zadaxin globally; excellent safety record

Storage

Stability & handling

❄️Lyophilized (powder)2–8°Cstable long-term
💉Reconstituted2–8°Cwithin 30 days
📈

Price tracking starts now.

Set an alert to get notified when this peptide drops.

Related pages

More on Thymosin Alpha-1

Stack & Compare

Frequently Researched Together

Research

Studies & key findings

  • Endogenous 28-amino-acid peptide derived from prothymosin α; approved (Zadaxin) in 35+ countries for chronic hepatitis B, hepatitis C, and as an adjuvant in cancer immunotherapy.
  • Phase 3 RCT in chronic HBV (1998) showed thymosin α1 plus interferon-α produced significantly higher seroconversion rates than interferon alone.

8 peer-reviewed sources cited — clinical, preclinical, and regulatory.

Read full research →
Failed to fetch